Gilead Sciences (GILD)
167.57
-6.91 (-3.96%)
NASDAQ · Last Trade: Nov 5th, 5:20 PM EST
News & Press Releases
Vir Bio (VIR) Q3 2026 Earnings Call Transcriptfool.com
Gilead deal and 2028 cash runway frame upcoming hepatitis data.
Via The Motley Fool · November 5, 2026
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi® (seladelpar) achieved the alkaline phosphatase (ALP) normalization composite endpoint defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥ 15% decrease from baseline. ALP is a key marker of disease activity and long-term outcomes in PBC. These results can expand understanding of treatment effects and inform evolving treatment goals for people living with PBC.
By Gilead Sciences, Inc. · Via Business Wire · November 5, 2026
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.fool.com
Gilead Sciences increased its quarterly dividend by 3.8% this year.
Via The Motley Fool · November 5, 2026
Gilead Sciences (NASDAQ:GILD): A Dividend Quality Candidate for Income Investorschartmill.com
Via Chartmill · October 31, 2026
Gilead Sciences (NASDAQ:GILD) Posts Q3 Beat but Shares Stay Flat as Raised Guidance Is Roughly In Linechartmill.com
Via Chartmill · October 29, 2026
What Vir Biotechnology (VIR) Said on Its Q3 Earnings Callmarketbeat.com
Vir Biotechnology (NASDAQ:VIR) expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 2027, executives said on the company’s third-quarter earnings call.
The company
Via MarketBeat · November 5, 2026
3 S&P 500 stocks we think twice about
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
Via StockStory · November 4, 2026
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (December 12–15, 2026).
By Gilead Sciences, Inc. · Via Business Wire · November 4, 2026
2 Nasdaq 100 stocks to own for decades and 1 we brush off
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Via StockStory · November 2, 2026
United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should ...
Via StockStory · November 2, 2026
Earnings to watch: Myriad Genetics (MYGN) reports Q3 results tomorrow
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Wednesday afternoon. Here’s what to expect. Myriad Genetics mi...
Via StockStory · November 2, 2026
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026), taking place from November 8-11. As a leader in HIV innovation, Gilead will share new clinical data and real-world evidence from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. Results from more than 50 studies, including late-breaking data and two oral presentations, along with Gilead-led symposia and community forums, reflect the company’s person-centered approach to advancing scientific discovery and the importance of partnership to help end the HIV epidemic.
By Gilead Sciences, Inc. · Via Business Wire · November 2, 2026
Amgen (AMGN) reports Q3: everything you need to know ahead of earnings
Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here’s what you need to know. Amgen beat analysts’ revenue exp...
Via StockStory · November 1, 2026
BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. Bio...
Via StockStory · November 1, 2026
1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in Novemberfool.com
The company is having a great year.
Via The Motley Fool · November 1, 2026
Vertex Pharmaceuticals earnings: what to look for from VRTX
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma...
Via StockStory · October 31, 2026
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
By Gilead Sciences, Inc. · Via Business Wire · October 30, 2026
GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loom
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year...
Via StockStory · October 30, 2026
S&P 500 Gap Movers for October 30, 2026chartmill.com
Via Chartmill · October 30, 2026
Gilead (GILD) Q3 2026 Earnings Call Transcriptfool.com
Base business sales surged 16%, marking strongest growth in over a decade.
Via The Motley Fool · October 30, 2026
S&P 500 Premarket Gainers and Losers on Oct. 30, 2026chartmill.com
Via Chartmill · October 30, 2026
What Gilead Sciences (GILD) Said on Its Q3 Earnings Callmarketbeat.com
Gilead Sciences (NASDAQ:GILD) reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove performance. The company also raised its full-year base business revenue outlook while outlining t
Via MarketBeat · October 29, 2026
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fallchartmill.com
Via Chartmill · October 29, 2026
Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.8% year on year to $8.3 billion...
Via StockStory · October 29, 2026
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decadeinvestors.com
Gilead Sciences crushed Wall Street's sales expectations on the back of its HIV treatments and cancer drug Trodelvy.
Via Investor's Business Daily · October 29, 2026